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Abstract: Stilbenes are compounds found in numerous medicinal plants and food products with some known 
biological and even antileishmanial activity. This paper describes the preparation of Aza-stilbene derivatives and 
their in vitro biological activities against Leishmania species. Most of the compounds with hydroxyl groups (2a, 
2b, 2d, 2e and 2f) showed interesting results against three Leishmania species tested. Compound 2f showed the 
best activity against intracellular forms of L. amazonensis, with IC50 of 7.48 µM, very similar when compared to 
reference drug Miltefosine. It not possible associate NO production with leishmanicidal activity for all  aza-
stilbene derivatives. It is noteworthy that none of compounds tested showed cytotoxicity against macrophages. 
 
Keywords: Aza-stilbene derivatives; stilbenes; antileishmanial activity; amastigote forms. 
 
 
Introduction 
   
Infectious and parasitic diseases are very common in tropical countries and affect the poor 
population,  often  below  the  poverty  line.  They  account  for  11%  of  diseases  worldwide, 
according to WHO data; these diseases are the cause of death of more than 14 million people 
a year, affecting more than one billion, which represents about one sixth of world population. 
Among these diseases, of the largest numbers of deaths, morbidity, and cause greater socio-
economic impact for developing countries, that’s including leishmaniasis 
1-3. 
  Leishmaniasis is caused by more than 20 protozoa species that belong genus Leishmania, 
transmitted by about 30 phlebotominae sandfly species. This disease is included as Neglected 
Tropical Diseases (NTDs), causing large political, economic and social impact
3. According to 
WHO estimations, leishmaniasis is endemic in 98 countries with incidence of 2 million new 
cases per year and 350 million people living in areas at risk worldwide
3-4. Depending on the 
parasite  species,  clinical  manifestations  may  comprises  a  wide  disease  spectrum  ranging Mediterr.J.Chem., 2013, 2(3),  D. T. S. de Paula
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localized cutaneous  lesions  to  mucocutaneous  form can lead to  disfigurement  beyond the 
visceral form which can be fatal if left untreated
3. 
  Current treatment of leishmaniasis is based on pentavalent antimonials, particularly the 
pentavalent  compound  (sodium  stibogluconate  and  meglumine  antimoniate),  and  play  a 
fundamental role in the therapy world for over 70 years
1,4,5. However, they are toxic and 
currently have known strong resistance, especially in India. There are other alternatives such 
as  amphotericin  B,  pentamidine,  but  both  have  also  high  toxicity,  parenteral  route  of 
administration, developing drug resistance and inadequate efficacy
4-6. Miltefosine, the first 
oral drug, was initially used for the treatment the cancer and have been used in treatment of 
leishmaniasis, but has high cost, is teratogenic and appearance of resistance strain, thus not 
recommended for pregnant women
4-6. 
  Natural  stilbenes  such  as  resveratrol,  piceatannol,  pinosilvin,  pterostilbene,  pinosilvin 
monoethyl ether and astringin (Figure 1) are compounds found in many plants (vines and 
pines)  and  also  in  various  foods  (peanuts  and  red  grapes)
7.  The  most  important  natural 
stilbene is resveratrol (3,5,4'-trihydroxystilbene). This compound is a secondary metabolite 
produced  by  roughly  70  species  of  plants  and  was  found  in  many  natural  foods  such  as 
grapes,  red wine and grape juice
8. Resveratrol  was first isolated from  the roots of White 
hellebore  (Veratrum  album)  in  1940  in  Japan,  and  later  was  found  in  medicinal  plants 
traditionally used in China and Japan
9.  Initially characterized as a phytoalexin, has achieved 
renown  in  the  scientific  literature  in  1992  when  it  was  postulated  as  responsible  for  the 
cardiac  protective  effects  of  wine  (an  effect  called  "French  paradox")
10,11.  Furthermore, 
several studies have shown that resveratrol can prevent or inhibit the progression of a variety 
of diseases such as cancer, cardiovascular disease, ischemic damage and other
-8,9,12. Recent 
studies suggest that resveratrol has parasitic activities, including effect against protozoan as 
Leishmania sp and Trichomonas vaginalis
13,14. 
 
 
Figure 1. Structures of natural stilbenes occurrence in higher plants. Gly = -D-
glucopyranoside. 
 
   Despite advances in research and development in the use of stilbenes, some studies have 
been  showed  that  stilbenes  being  well  absorbed  by  the  body,  these  molecules  have  low 
bioavailability, which is a limiting factor for their widespread use as medicine
8,9. This fact Mediterr.J.Chem., 2013, 2(3),  D. T. S. de Paula
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justifies the importance of searching for molecules similar to stilbenes that retain activity, but 
with better bioavailability. In recent work our research group proposes the use of bioisoster
15 
(Figure 2)
 to obtain analogues of stilbenes, more specifically aza-stilbenes obtained by the 
classical reaction of formation of imines
16,17.   
 
 
 
Figure 2. Bioisosterism tool utilized for development of new derivates. 
 
Experimental Section 
 
Antileishmanial activity 
Antipromastigote  activity:  three  Leishmania  species  were  used:  L.  amazonensis 
(IFLA/Br/67/PH8), L. major (MRHO/SU/59P) and L. braziliensis (MHOM/Br/75/M2903). 
Antileishmanial activity of compounds was initially established in promastigotes. Briefly, log-
phase promastigotes of Leishmania were incubated with or without compounds at various 
concentrations in 96-well tissue culture plates for 72 h at 24°C and cell viability was assessed 
using  MTT  colorimetric  method,  as  described  previously
18,19.  Miltefosine  was  used  as 
positive control. Controls containing 0.5% DMSO and medium alone were also included. 
Results were expressed as the concentration inhibited 50% of cell growth (IC50). 
 
Antiamastigote  activity:  peritoneal  macrophages  were  obtained  from  BALB/c  mice 
previously inoculated with 3% thioglycolate medium. Adherent macrophages (2x10
5 cells per 
well) were infected with stationary-phase promastigotes Leishmania and incubated for 3 h at 
33°C in 5% CO2. Non-phagocytosed promastigotes were removed by washing and infected 
macrophages were incubated with compounds (100.0, 50.0, 25.0, 12.5 and 6.25 μM) for 72 h 
at 33°C in 5% CO2. Cells were fixed and stained with Giemsa for parasite counting and 
examined  microscopically  for  intracellular  amastigotes.  Results  were  expressed  the 
concentration  inhibited  50%  of  cell  growth  (IC50).  Index  of  infection  was  obtained  by 
multiplying  the  percentage  of  infected  cells  by  number  of  amastigotes  and  dividing  by 
number total cells (infected and non-infected). Miltefosine was used as the reference drug. 
 
Cytotoxicity assay against mammalian cells 
  Peritoneal macrophages from mice BALB/c were used for cytotoxicity assay. The cells 
were  incubated  in  different  concentrations  of  the  compounds  and  cell  viability  was 
determined  with  the  MTT  assay  and  was  confirmed  by  comparing  the  control  group 
morphology via light microscopy. 
 
Nitric oxide (NO) production 
  NO production was determined in an aliquota (50 μL) of the supernatants of Leishmania-
macrophages after 48 h in the presence of the compounds. Assay was performed as described 
by Green et al. (1982)
20 and as described previously
19. Absorbance was measured at 540 nm Mediterr.J.Chem., 2013, 2(3),  D. T. S. de Paula
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using  a  microplate  reader  (Multiskan  MS  microplate  reader,  LabSystems  Oy,  Helsink, 
Finland). Nitrite content was quantified by extrapolation from sodium nitrite standard curve in 
each experiment. All the assays were carried out in duplicate. Positive control: 10 μg/ml of 
lipopolysaccharide (LPS) from Escherichia coli J5 (Sigma-Aldrich).  
 
Statistical analysis 
  For promastigote forms of Leishmania assay and cytotoxicity on macrophages, the IC50 
values  were  carried  out  at  5%  significance  level  (p  <  0.05,  CI  95%),  calculated  using  a 
nonlinear regression curve, by using GraFit Version 5 software (Erithacus Software, Horley, 
U.K). For amastigote Leishmania assays, the IC50 values were calculated from the program 
Probit using methods of Lichtfield and Wilcoxon and the statistical analysis was performed 
with  the  program  GraphPad  Prism  4  (GraphPad  Software,  San  Diego,  CA).  One-way 
ANOVA was applied to compare all the groups. To compare the control with each compound, 
concentration was applied Dunnett post-test. Differences were regarded as significant when p 
< 0.0001 (***) and p < 0.001 (**). 
 
 
Results and Discussion 
Chemistry 
  Formation of similar reaction was performed by condensation of aromatic amines (aniline, 
4-hydroxyaniline, 1,2-phenylenediamine and 4-aminosalicylic acid) with aromatic aldehydes 
(benzaldehyde, p-anisaldehyde, p-hydroxybenzaldehyde, vanillin, salicylaldehyde, 3,4,5-tri-
methoxybenzaldehyde, 4-dimethylaminobenzaldehyde and 4-nitrobenzaldehyde), using EtOH 
or MeOH as solvent at room temperature as shown in Scheme 1. 
 
 
Scheme 1. Synthetic pathway for Aza-stilbene derivatives. 
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Methods performed to characterize the synthesized compounds were 
1H NMR, 
13C, IR and 
melting points. These data are presented in Table 1 and are in agreement with the literature
21-
34. 
Table 1. Spectral data of aza-stilbene derivatives. 
Compound  CH=N   C=N    C=N  Melting Point   Yield (%) 
1a  8.44  160.0  1602  89.2-90.7 (89.2-90.7)
24  74.0 
1b  8.96  163.5  1614  50.7-51.4 (50,0-50,5)
30  63.0 
1c  8.51  159.8  1602  61.4-62.1 (62,7-63,4)
24  65.0 
1d  8.43  160.2  1622  53.1-54.2 (52,0-53,0)
31  63.0 
1e  7.58  159.9  1629  133.8-134.4 (135,0)
32  87.0 
1f  8.39  159.9  1600  96.8-97.3 (97,0-98,0)
33  72.0 
1g  8.80  158.8  1600  89.6-90.7 (90,0-90,5)
24  75.0 
2a  8.38  156.9  1610  182.7 (182,0-184,0)
34  63.0 
2b  8.43  160.2  1607  203.7 (203,0 – 205,0)
34  62.0 
2c  8.89  160.2  1616  141.4 (140,0)
35  55.0 
2d  8.51  161.5  1609  189.0 (187,0)
36  67.0 
2e  8.42  157.2  1606  197.0 (198,0)
37  60.0 
2f  8.51  157.0  1624  185.4  68.0 
2g  8.38  156.9  1610  182.7 (182-184)
38  79.0 
2h  8.73  157.3  1624  172.1 (168,5)
39  76.0 
3a  9.78  172.2  1602  182.4 (175,0-180,0)
40  57.0 
3b  10.26  172.0  1606  158.6 (156,0-158,0)
41  73.0 
3c  9.66  172.0  1605  190.0-191.5 (189,0-190,0)
42  59.0
 
*NMR experiments were performed at 300 MHz for 1H and 75 MHz for 
13C in DMSO-d6 (ppm) and I.R. 
experiments was performed at KBr support (cm
-1). M.P. Data (° C) were compared to literature data which are 
given in parentheses. 
 
Signals between  7.58-10.26 ppm (
1H NMR) refer to C-H imine it’s an indication of 
imine formation for the aza-stilbene derivative. Additionally the analysis of 
13C NMR specter 
showed a signal at  157.0-172.2 ppm referent at carbon C=N of imine. 
 
Biological 
 
  In  a  preliminary  screening,  eighteen  aza-stilbene  derivatives  were  assayed  against 
promastigote forms of L. amazonensis, L. braziliensis and L. major. Parasites were incubated 
with the compounds for 72 hours at 24°C in different concentrations. Results were expressed 
as the concentration inhibiting parasite growth by 50% (IC50). Among the compounds tested, 
only  compounds  2a,  2b,  2d,  2e  and  2f  showed  activity  against  promastigote  forms  of 
Leishmania with IC50 values ranging from 14.5 to 50.46 µM (Table 2).  Mediterr.J.Chem., 2013, 2(3),  D. T. S. de Paula
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Table 2.  In vitro activities of the compounds against promastigote forms of  Leishmania 
species and murine macrophages. 
  IC50 (µM)
a                      
Compounds  L. amazonensis  L. braziliensis  L. major  Macrophages 
1a  > 100.00  > 100.00  > 100.00  > 100.00 
1b  > 100.00  > 100.00  31.49±2.76  > 100.00 
1c  > 100.00  > 100.00  > 100.00  > 100.00 
1d  > 100.00  > 100.00  > 100.00  > 100.00 
1e  > 100.00  > 100.00  > 100.00  > 100.00 
1f  > 100.00  > 100.00  > 100.00  > 100.00 
1g  > 100.00  > 100.00  > 100.00  > 100.00 
2a  16.77±0.47  17.22±0.15  > 87.00  >100.00 
2b  36.98±0.73  > 87.00  20.27±2.98  >100.00 
2c  > 87.00  > 87.00  > 87.00  >100.00 
2d  20.69±0.33  43.37±3.90  16.32±1.19  >100.00 
2e  16.95±1.32  50.46±0.59  14.5±0.19  >100.00 
2f  35.81±2.57  30.71±2.36  > 87.00  >100.00 
2g  > 87.00  > 87.00  > 87.00  >100.00 
2h  > 87.00  > 87.00  > 87.00  >100.00 
3a  > 87.00  > 87.00  > 87.00  >100.00 
3b  > 87.00  > 87.00  > 87.00  >100.00 
3c  > 87.00  > 87.00  > 87.00  >100.00 
Miltefosine
b  21.39±1.18  28.07±0.47  20.00±0.51  >100.00 
aData  are  IC50  values  in  μM  ±  standard  deviation.  These  data  represents  the  average  of  3  independent 
experiments. 
bMiltefosine was used as reference drug. 
 
In this work aza-stilbene derivatives  were assayed against three main  Leishmania species 
which  affect  humans  and  related  to  cutaneous  manifestations:  L.  braziliensis  and  L. 
amazonensis are reported in Latin America and L. major is found in several countries of the 
Old World. In general, the compounds tested showed varying activity against all Leishmania 
species tested. This fact is not uncommon and has been reported by several authors
19,  35. 
However,  it  is  interesting  when  a  compound  shows  activity  against  several  Leishmania 
species since this reinforces their leishmanicidal property. Regarding this, the compounds 2d 
and  2e  which  have  methoxy  group  and  methoxy  group  with  hydroxyl  in  ortho-position, 
respectively, were active in all Leishmania species tested. Compound 2e showed also the best 
leishmanicidal activity with IC50 of 14.5 µM against promastigotes of L. major. Furthermore, 
several compounds showed more active than to miltefosine, which was used as reference 
drug. 
With respect the cytotoxicity of aza-stilbene derivatives on peritoneal macrophages, no 
compounds showed toxicity against these mammalian cells (Table 2). As can be observed all 
compounds tested showed IC50 values > 100 µM. These results are very interesting because 
data  from  our  laboratory  has  indicated  that  peritoneal  macrophages  are  cells  with  strong 
sensibility for in vitro assays in comparing to immortal cell lines, as J744A1 macrophages
19 . 
In view of the good results of the aza-stilbene against promatigotes, we decided to choose 
the series 2a, 2b, 2d, 2e and 2f to test in amastigotes, which is a intracellular parasite and are 
responsible  for  clinical  manifestations  in  humans
36,37.  Table  3  shows  the  effect  of  these 
compounds  against  intracellular  forms  of  Leishmania  species.  Compounds  containing Mediterr.J.Chem., 2013, 2(3),  D. T. S. de Paula
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hydroxyl grouping 2a, 2b, 2d, 2e and 2f showed a significant activity against amastigotes of 
L. amazonensis with IC50 values below of 25.0 µM. These results are consistent with the 
literature, since the some authors demonstrated leishmanicidal activity of stilbene analogs
13.  
These stilbene analogs are poly-hydroxylated compounds, have C-4 hydroxyl in aromatic ring 
on their structures and all active compounds tested against Leishmania amastigotes showed 
superior  results  when  compared  to  resveratrol
13.  Furthermore,  analogs  of  resveratrol  also 
exhibited antitumor, antioxidant, and anti-inflammatory activities
38. 
 
Table 3. In vitro activities of the compounds against intracellular amastigotes of Leishmania. 
  CI50 (µM) 
(95% C.I.)
a 
Compostos  L. amazonensis  L. braziliensis  L. major 
2a  18.74 (13.55-25.90)  75.80 (49.41-116.30)  - 
2b  24.35 (20.19-29.36)  -  29.18 (20.82-40.91) 
2d  15.20 (9.67-23.87)  59.00 (38.44-90.55)  27.15 (20.69-35.63) 
2e  21.72 (15.88-29.70)  70.30 (51.51-95.93)  39.11 (26.76-57.16) 
2f  7.48 (4.36-12.85)  61.57 (35.31-107.37)  - 
Miltefosine  4.15 (2.89-5.96)  3.21 (2.26-4.61)  7.56 (6.35-8.98) 
Peritoneal macrophages previously infected with Leishmania promastigotes in the stationary growth phase were 
exposed to the compounds for 72h. Results from two assays in duplicate are shown as IC50 values in μM. 
aCI: Confidence interval. 
 
Compound 2f showed the best activity against intracellular forms of L. amazonensis, with 
IC50 of 7.48 µM (Table 3).  This compound presents in its structure the largest degree of 
substitution  on  the  aromatic  rings,  tetrasubstituded,  three  methoxyl  groups,  that  possibly 
confer a greater cellular penetration. It is interesting to note that compound 2f showed IC50 
value  near  to  IC50  of  miltefosine  (4.15  µM).  Miltefosine  is  recommended  to  treat 
leishmaniasis in endemic countries with related resistance to antimonials and has been used 
for treatment of visceral leishmaniasis in India and Ethiopia, and cutaneous leishmaniasis in 
Colombia, Bolivia and Guatemala
39. 
Furthermore,  figure  3  also  furnishes  information  about  leishmanicidal  activity  of  the 
compound 2f against amastigotes of L. amazonensis. When the parasites were treated with 
this  compound,  a  significant  dose-dependent  decrease  of  intracellular  amastigotes  was 
observed. 
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Figure 3: Effect of the compound 2f on L. amazonensis interiorized in peritoneal macrophage 
cells. Statistically significant difference of control: **p < 0.001, *p < 0.0001 . Mediterr.J.Chem., 2013, 2(3),  D. T. S. de Paula
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Table 4 shows selectivity and specificity of compounds tested. Regarding this, selectivity 
furnishes an idea about the toxicity selective action on the compounds on macrophages and it 
is obtained by dividing IC50 of macrophages by IC50 of intracellular amastigote forms. In 
general,  all  compounds  showed  good  selectivity,  being  more  destructive  for  intracellular 
parasite than to the mammalian cells. In a special remark for the compound 2f which showed 
the best anti-amastigote activity, it was at least 13 times more toxic for amastigote forms of L. 
amazonensis than to murine macrophages. Specificity provides insight about the behavior of 
the compounds on the both parasite stages. Muydler and coworkers
40 determined a cut-off 
values to evaluate the specificity of the compounds in amastigote or promastigote form of 
Leishmania: specificity value >2 define a compound as more active against the intracellular 
amastigote stage; while a specificity value <0.4 indicate a compound more active against 
promastigotes; compounds with specificity values between 0.4 and 2 were considered active 
against both stages
40. In accordance with this, our results showed that most of the compounds 
were active in both promastigote and amastigote stages, except the compound 2f which was 
more  active  against  intracellular  forms  with  specificity  value  of  4.79.  Furthermore,  the 
compound  2f  has  specificity  value  near  that  of  miltefosine  (4.79  and  5.15,  respectively), 
indicating  that  the  compound  2f  and  miltefosine  exhibit  similar  activities  to  intracellular 
amastigotes of L. amazonensis (Table 4). 
 
Table 4: Selectivity and specificity of Aza-stilbene derivatives. 
 
Compounds 
L. amazonensis  L. braziliensis  L. major 
SE
a   SP
b   SE
a   SP
b   SE
a   SP
b  
2a  >5.34  0.89  >1.32  0.23  -  - 
2b  >4.11  1.52  -  -  >3.43  0.69 
2d  >6.58  1.36  >1.69  0.73  >3.68  0.60 
2e  >4.60  0.78  >1.42  0.72  >2.56  0.37 
2f  >13.37  4.79  >1.62  0.50  -  - 
Miltefosine  >24.10  5.15  >31.15  8.74  >13.23  2.64 
aSE (selectivity): CC50 of macrophages/IC50 of amastigotes of Leishmania.  
cSP (specificity): is the ratio between promastigote IC50 and intracellular amastigote IC50.  
 
According to the results presented in this work, can be observe differences in sensitivity 
between  promastigote  and  amastigote  forms  of  Leishmania  in  relation  to  the  aza-stilbene 
assayed.  Several  factors  can  explain  this:  both  parasite  stages  have  different  host, 
promastigotes lives in the gut of the insect vector and amastigotes within mammalian cells; 
and  these  forms  present  biochemistry  and  morphology  differences  which  can  reflect  in 
different targets for the drugs. These differences in sensitivity between both stages of parasite 
several compounds were also verified by several authors
19,35,37,40.  
  Macrophages are the major immunologic route for elimination of Leishmania. Activated 
macrophages release a variety of cytotoxic molecules which include NO with action against 
Leishmania
41,42. So, we tried to investigate if the leishmanicidal effect of the aza-stilbene 
derivatives could be associated to NO production. This assay was performed in parallel with 
the antiamastigote assay, collecting the supernatants of Leishmania-macrophages treated with 
several concentrations of the aza-stilbene derivatives.  In general, majority of the derivatives 
tested  induced  significant  nitrite  production  in  the  culture  medium  only  at  the  maximum 
concentration tested (100 µM) compared to untreated control (data not shown). However, in Mediterr.J.Chem., 2013, 2(3),  D. T. S. de Paula
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low concentration, mainly close the IC50 values of each compound, it was observed variation 
on NO level production and in fact some even inhibited the spontaneous NO production and it 
not  possible  associate  NO  production  with  leishmanicidal  activity  for  all  aza-stilbene 
derivatives. 
 
Conclusion 
 
In this paper, we show that some Aza-stilbene derivates with hydroxyl groups exhibit 
leishmanicidal activity against three Leishmania species. Compound 2f was the most active 
against  intracellular  forms  of  L.  amazonensis,  presenting  results  near  the  reference  drug 
miltefosine. However, further studies are needed to identify the likely mechanism of action of 
this  drug.  Nevertheless,  the  results  indicate  the  Aza-stilbene  derivatives  as  a  promising 
research line. 
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